Abstract:Background: Cisplatin (DDP) is among the most widely used chemotherapeutic drugs for non-small cell lung cancer (NSCLC), yet the frequent emergence of chemoresistance serves as a major barrier to the treatment of this tumor type. Long non-coding RNAs (lncRNAs) have recently been shown to influence the ability of cells to resist particular chemotherapy drugs. The present study was developed to explore the role of the lncRNA SNHG7 as a regulator of NSCLC cell chemosensitivity. Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to measure SNHG7 expression in NSCLC tissues from patients that were sensitive/resistant to DDP, correlations between SNHG7 expression levels and the patients' clinicopathological characteristics were assessed, and the prognostic relevance of SNHG7 expression was examined via the Kaplan-Meier approach. In addition, SNHG7 expression was assessed in NSCLC cell lines that were DDP-sensitive or -resistant, while western blotting and immunofluorescence staining were employed to detect autophagy-associated protein expression in A549, A549/DDP, HCC827, and HCC827/DDP cells. NSCLC cell chemoresistance was quantified via the Cell Counting Kit-8 (CCK-8) assay approach, and flow cytometry was used to detect the apoptotic death of these tumor cells. The chemosensitivity of xenograft tumors in vivo was further assessed to validate the functional importance of SNHG7 as a regulator of NSCLC DDP resistance. Results: Relative to paracancerous tissues, NSCLC tumors exhibited SNHG7 upregulation, and this lncRNA was further upregulated in DDP-resistant patients compared to chemosensitive patients. Consistently, higher SNHG7 expression levels were correlated with worse patient survival outcomes. DDP-resistant NSCLC cells were also found to exhibit higher levels of SNHG7 expression than chemosensitive cells, and knocking down this lncRNA enhanced the sensitivity of these cells to DDP treatment, resulting in impaired proliferation and higher rates of apoptotic death. Knocking down SNHG7 was also sufficient to suppress microtubule associated protein 1 light chain 3 beta (LC3B) and Beclin1 protein levels and promote p62 upregulation in vitro. The silencing of this lncRNA additionally inhibited the resistance of NSCLC xenograft tumors to DDP treatment in vivo. Conclusions: SNHG7 can promote malignant behaviors and DDP resistance in NSCLC cells at least partly via the induction of autophagic activity.

LncRNA NONHSAT141924 promotes paclitaxel chemotherapy resistance through p-CREB/Bcl-2 apoptosis signaling pathway in breast cancer

Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer

Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness

Long Non-Coding RNA BC087858 Induces Non-T790m Mutation Acquired Resistance to EGFR-TKIs by Activating PI3K/AKT and MEK/ERK Pathways and EMT in Non-Small-cell Lung Cancer

Microarray Expression Profile of Long Non-Coding RNAs in Paclitaxel-Resistant Human Lung Adenocarcinoma Cells.

LncRNAs in modulating cancer cell resistance to paclitaxel (PTX) therapy

LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability

Genome-wide Profiling of Long Non-Coding RNA Expression Patterns in Anthracycline-Resistant Breast Cancer Cells.

Long non‐coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation

lncRNA NEAT1 promotes the Taxol resistance of breast cancer via sponging the miR-23a-3p-FOXA1 axis

LncRNA NONHSAT227443.1 Confers Esophageal Squamous Cell Carcinoma Chemotherapy Resistance by Activating PI3K/AKT Signaling via Targeting MRTFB

lncRNA <i>MALAT1</i> regulates the resistance of breast cancer cells to paclitaxel via the miR-497-5p/<i>SHOC2</i> axis

RETRACTED ARTICLE: LncRNA CCAT1 Modulates the Sensitivity of Paclitaxel in Nasopharynx Cancers Cells Via Mir-181A/cpeb2 Axis

LINC00461 Overexpression Can Induce Docetaxel Resistance in Breast Cancer by Interacting with miR-411-5p.

LINC00337 Induces Tumor Development and Chemoresistance to Paclitaxel of Breast Cancer by Recruiting M2 Tumor-Associated Macrophages

LncRNA H19 Confers Chemoresistance in ERα-positive Breast Cancer Through Epigenetic Silencing of the Pro-Apoptotic Gene BIK

Downregulation of LINC01296 Suppresses Non-Small-cell Lung Cancer Via Targeting Mir-143-3p/atg2b.

Inhibition of XIST Restrains Paclitaxel Resistance in Breast Cancer Cells by Targeting Hsa-Let-7d-5p/atg16l1 Through Regulation of Autophagy

Next Generation Deep Sequencing Identified a Novel Lncrna N375709 Associated with Paclitaxel Resistance in Nasopharyngeal Carcinoma

Low Expression of Lncrna CTB-104H12.5 Induces Resistance to Adriamycin in HER2 Negative Breast Cancer by Downregulating GAS7C

LncRNA SNHG7 promotes non-small cell lung cancer progression and cisplatin resistance by inducing autophagic activity